Categorynews

FSD Pharma Welcomes All-Star Lineup of Cannabis Researchers to Scientific Advisory Board

May 20, 2019 Off By BusinessWire

Daniele Piomelli, Ph.D., Ryan Vandrey, Ph.D. and David Casarett, MD, MA
Join distinguished group of Scientific Advisors

TORONTO–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/FSDDF?src=hash" target="_blank"gt;#FSDDFlt;/agt;–FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) (“FSD” or the
“Company”), is pleased to announce that three eminent cannabis
researchers have joined the company’s Scientific Advisory Board (“SAB”).

“We are honored to welcome Daniele Piomelli, Ph.D., Ryan Vandrey, Ph.D.
and David Casarett, MD, MA to our Scientific Advisory Board,” said Dr.
Raza Bokhari, FSD Executive Co-Chairman & Chief Executive Officer. “This
trio of world-renowned experts will play a key role in our company’s
scientific and clinical development programs. Their guidance will be
invaluable in shaping the biopharmaceutical strategic direction of the
company.”

The new members include:

Daniel Piomelli, Ph.D.

Dr. Piomelli is the Louise Turner Arnold Chair in Neurosciences and
Distinguished Professor of Anatomy and Neurobiology, Pharmacology and
Biological Chemistry at the University of California, Irvine, where he
is also the Director of the Center for the Study of Cannabis. He has
authored more than 400 peer-reviewed articles in high-impact journals,
three full-length books and 34 patents and founded the Department of
Drug Discovery and Development at the Italian Institute of Technology in
Genoa, Italy, which he directed from 2007 to 2016. He is Editor-in-Chief
of Cannabis and Cannabinoid Research, the only peer-reviewed
journal entirely dedicated to the scientific, medical, and psychosocial
exploration of clinical cannabis, cannabinoids, and the endocannabinoid
system.

Ryan Vandrey, Ph.D.

Dr. Vandrey is an experimental psychologist and an Associate Professor
at the Behavioral Pharmacology Research Unit at Johns Hopkins
University. Dr. Vandrey’s research focuses primarily on the impact of
route of administration, dose, and chemical composition of cannabis
products on resultant drug effects and pharmacokinetics. In addition,
Dr. Vandrey has been involved with a broad range of studies related to
the risks and benefits of medicinal cannabis use, the effects of
cannabis use on sleep, cannabis withdrawal and the treatment of Cannabis
Use Disorder, cannabis product testing, and developing measures of
cannabis use behavior.

David Casarett, MD, MA

Dr. Casarett is a professor of Medicine at Duke University and the Chief
of Palliative Care for Duke Health where he directs the Duke Center for
Palliative Care. He is the author of more than 140 articles in journals
including The Journal of the American Medical Association and The
New England Journal of Medicine. His writing has appeared in
national publications including the New York Times, and Wired.
Dr. Casarett is also the author of three non-fiction books, the most
recent of which was Stoned: A Doctor’s Case for Medical
Marijuana, published in 2015 by Penguin Random House. He is the
principal of Cannabis Outcomes, a full-service research and consulting
group focused on bringing methodologic expertise to medical cannabis
research and care delivery. His work in the cannabis space has included
founding roles in startups that focus on growing/dispensing (Curio
Wellness; CleverLeaves), genetic testing (MelixGx), data tracking (Evio
Labs), and research (Zelda; Clinicann).

The SAB will continue to guide FSD Pharma in emerging as a leader in the
field of cannabinoid therapeutics. The Board is led by chairman Charles
V. Pollack, Jr., M.A., M.D., FACEP, FAAEM, FAHA, FACC, FESC, FCPP, an
international leader in emergency medicine and founder of The Lambert
Center for the Study of Medicinal Cannabis and Hemp at Thomas Jefferson
University. The Board will continue to bring on well-known medical
professionals with extensive research, academic and industry experience.

About FSD Pharma
FSD Pharma is focused on the development of
the highest quality indoor grown, pharmaceutical grade cannabis and on
the research and development of novel cannabinoid-based treatments for
several central nervous system disorders, including chronic pain,
fibromyalgia and irritable bowel syndrome. The Company has 25,000 square
feet that is licensed at its Ontario facility and expansion is currently
underway.

FSD facilities sit on 70 acres of land with 40 acres primed for
development and an expansion capability of up to 3,896,000 square feet.

FSD’s wholly-owned subsidiary, FV Pharma, is a licensed producer under
the Cannabis Act and Regulations, having received its cultivation
license on October 13, 2017 and its Sale for Medical Purposes license on
April 18, 2019. FV Pharma’s vision is to transform its current
headquarters in a Kraft plant in Cobourg, Ontario into the largest
hydroponic indoor grow facility in the world. FV Pharma intends to cover
all aspects of this exciting new industry, including cultivation, legal,
processing, manufacturing, extracts and research and development. For
additional information on the company, please visit our website at www.fsdpharma.com.

Forward-Looking Information
Neither the Canadian
Securities Exchange nor its regulation services provider accept
responsibility for the adequacy or accuracy of this release.

Certain statements contained in this press release constitute
forward-looking information. These statements relate to future
events or future performance. The use of any of the words “could”,
“intend”, “expect”, “believe”, “will”, “projected”, “estimated” and
similar expressions and statements relating to matters that are not
historical facts are intended to identify forward-looking information
and are based on FSD Pharma’s current belief or assumptions as to the
outcome and timing of such future events. Actual future results may
differ materially. Actual results and developments may differ materially
from those contemplated by these. The forward-looking information
contained in this press release is made as of the date hereof, and FSD
Pharma is not obligated to update or revise any forward-looking
information, whether as a result of new information, future events or
otherwise, except as required by applicable securities laws. Because of
the risks, uncertainties and assumptions contained herein, investors
should not place undue reliance on forward looking-information. The
foregoing statements expressly qualify any forward-looking information
contained herein.